Brian Koh

Brian Koh has worked in the healthcare industry since 2015. Brian began their career at Gilead Sciences as an Associate Director of Clinical Research/Development in Hematology/Oncology. Brian was promoted to Director in the same role in 2017 and Senior Director in 2018. In 2018, they moved to Kite Pharma as a Director of Clinical Research/Development in Hematology/Oncology and was promoted to Senior Director in the same role. In 2021, they moved to Vividion Therapeutics. Inc. as the Head of Translational Sciences and Clinical Development. Most recently, they joined PrognomiQ Inc. as the Chief Medical Officer in 2022.

Brian Koh received their Bachelor's Degree in Biological Anthropology from Harvard University. Brian then earned their Master's Degree in Molecular, Cellular, and Developmental Biology from Yale University. Brian continued their education at Yale University School of Medicine, where they obtained their Doctor of Medicine (M.D.) degree. After this, they completed a residency in Internal Medicine, Clinician Investigator (CI)/ABIM Research Pathway at Mayo Clinic School of Graduate Medical Education. Brian then went on to pursue a fellowship in Clinical Pharmacology, NIH T32 Training Program at Mayo Clinic Graduate School of Biomedical Sciences. Finally, they completed a fellowship in Hematology and Medical Oncology, Clinician Investigator (CI)/ABIM Research Pathway at Mayo Clinic School of Graduate Medical Education.